Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease

Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease (Breathtec Biomedical)

Nash Pharmaceuticals Inc., a wholly owned subsidiary of UF startup Breathtec Biomedical Inc., is pleased to announce that its lead compound for non-alcoholic steatohepatitis (“NASH”) NP-160 showed positive results in a recently completed study investigating its therapeutic effects in the widely used STAM™ mouse model from SMC Laboratories. NP-160 is one of a number of already approved compounds that Nash Pharma has been screening for new therapeutic uses as part of its drug repurposing strategy.

Learn more about Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease.

X